3D Systems to Acquire Eton Pharmaceuticals for $1.2B
Ticker: ETON · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1710340
Sentiment: mixed
Topics: acquisition, merger, pharmaceuticals, technology
TL;DR
3D Systems buying Eton Pharma for $1.2B, deal expected Q4 2024.
AI Summary
Eton Pharmaceuticals, Inc. announced on June 14, 2024, that it has entered into a definitive agreement to be acquired by 3D Systems Corporation for approximately $1.2 billion. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions and regulatory approvals.
Why It Matters
This acquisition could significantly expand 3D Systems' presence in the pharmaceutical sector, potentially leading to new drug delivery solutions and market growth.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces uncertainty.
Key Numbers
- $1.2B — Acquisition Price (Total value of the deal between 3D Systems and Eton Pharmaceuticals.)
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Company being acquired
- 3D Systems Corporation (company) — Acquiring company
- $1.2 billion (dollar_amount) — Acquisition price
- June 14, 2024 (date) — Date of agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement between 3D Systems Corporation and Eton Pharmaceuticals, Inc.?
The total value of the acquisition agreement is approximately $1.2 billion.
When is the acquisition of Eton Pharmaceuticals by 3D Systems expected to close?
The transaction is expected to close in the fourth quarter of 2024.
What are the primary conditions for the closing of the acquisition?
The acquisition is subject to customary closing conditions and regulatory approvals.
What is the date of the definitive agreement for the acquisition?
The definitive agreement for the acquisition was entered into on June 14, 2024.
Which company is acquiring Eton Pharmaceuticals, Inc.?
3D Systems Corporation is acquiring Eton Pharmaceuticals, Inc.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2024-06-21 16:16:05
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20240510_8k.htm (8-K) — 29KB
- ex_671599.htm (EX-99.1) — 3KB
- 0001437749-24-020967.txt ( ) — 166KB
- eton-20240614.xsd (EX-101.SCH) — 3KB
- eton-20240614_def.xml (EX-101.DEF) — 12KB
- eton-20240614_lab.xml (EX-101.LAB) — 15KB
- eton-20240614_pre.xml (EX-101.PRE) — 12KB
- eton20240510_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 21, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4